These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11357498)

  • 41. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
    Raderer M; Kurtaran A; Leimer M; Angelberger P; Niederle B; Vierhapper H; Vorbeck F; Hejna MH; Scheithauer W; Pidlich J; Virgolini I
    J Clin Oncol; 2000 Mar; 18(6):1331-6. PubMed ID: 10715305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid.
    Fujishita T; Kishida M; Taki H; Shinoda C; Miyabayashi K; Fujishita M; Maruyama M; Mizushima Y; Kobayashi M
    Respirology; 2007 Nov; 12(6):928-30. PubMed ID: 17986127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
    Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
    Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
    Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
    Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas.
    Jing H; Li F; Wang L; Wang Z; Li W; Huo L; Zhang J
    Clin Nucl Med; 2017 Jul; 42(7):525-529. PubMed ID: 28481789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
    Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
    Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
    Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of primary pulmonary carcinoid tumors using FDG PET.
    Erasmus JJ; McAdams HP; Patz EF; Coleman RE; Ahuja V; Goodman PC
    AJR Am J Roentgenol; 1998 May; 170(5):1369-73. PubMed ID: 9574618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multimodality imaging features in a case of bronchial carcinoid including FDG PET.
    Shin V; Bhargava P; Brown J; Ames ED; Kang P
    Med Sci Monit; 2007 Jan; 13(1):CS4-8. PubMed ID: 17179913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.
    Krüger S; Buck AK; Blumstein NM; Pauls S; Schelzig H; Kropf C; Schumann C; Mottaghy FM; Hombach V; Reske SN
    J Intern Med; 2006 Dec; 260(6):545-50. PubMed ID: 17116005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [111IN-octreotide and 123I-MIBG scintigraphy in the diagnosis of small intestinal carcinoid tumors--results of a comparative investigation].
    Dresel S; Tatsch K; Zachoval R; Hahn K
    Nuklearmedizin; 1996 Apr; 35(2):53-8. PubMed ID: 8721576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.
    Donati OF; Hany TF; Reiner CS; von Schulthess GK; Marincek B; Seifert B; Weishaupt D
    J Nucl Med; 2010 May; 51(5):692-9. PubMed ID: 20395324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67.
    Belhocine T; Foidart J; Rigo P; Najjar F; Thiry A; Quatresooz P; Hustinx R
    Nucl Med Commun; 2002 Aug; 23(8):727-34. PubMed ID: 12124477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
    Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
    Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?
    Pasquali C; Rubello D; Sperti C; Gasparoni P; Liessi G; Chierichetti F; Ferlin G; Pedrazzoli S
    World J Surg; 1998 Jun; 22(6):588-92. PubMed ID: 9597933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.
    Franzius C; Hermann K; Weckesser M; Kopka K; Juergens KU; Vormoor J; Schober O
    J Nucl Med; 2006 Oct; 47(10):1635-42. PubMed ID: 17015899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.